Adenovirus-Vectored Vaccine Provides Postexposure Protection to Ebola Virus-Infected Nonhuman Primates

Gary Wong; Jason S. Richardson; S. Pillet; Trina Racine; Ami Patel; Geoff Soule; Jane Ennis; Jeffrey Turner; Xiangguo Qiu; Gary P. Kobinger

doi:10.1093/infdis/jiv102

Adenovirus-Vectored Vaccine Provides Postexposure Protection to Ebola Virus-Infected Nonhuman Primates

Gary Wong, Jason S. Richardson, S. Pillet, Trina Racine, Ami Patel, Geoff Soule, Jane Ennis, Jeffrey Turner, Xiangguo Qiu, Gary P. Kobinger

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Abstract

Ebola virus (EBOV) causes lethal disease in up to 90% of EBOV-infected humans. Among vaccines, only the vesicular stomatitis virus platform has been successful in providing postexposure protection in nonhuman primates. Here, we show that an adjuvanted human adenovirus serotype 5 (Ad5)-vectored vaccine (Ad5-Zaire EBOV glycoprotein) protected 67% (6 of 9) and 25% (1 of 4) of cynomolgus macaques when administered 30 minutes and 24 hours following EBOV challenge, respectively. The treatment also protected 33% of rhesus macaques (1 of 3) when given at 24 hours. The results highlight the utility of adjuvanted Ad5 vaccines for rapid immunization against EBOV.

Original language	English (US)
Pages (from-to)	S379-S383
Journal	Journal of Infectious Diseases
Volume	212
DOIs	https://doi.org/10.1093/infdis/jiv102
State	Published - Oct 1 2015
Externally published	Yes

Keywords

Ebola
adenovirus
nonhuman primates
post-exposure
vaccine

ASJC Scopus subject areas

General Medicine

Access to Document

10.1093/infdis/jiv102

Cite this

@article{c7371a086c424ba095433d42f523ee19,

title = "Adenovirus-Vectored Vaccine Provides Postexposure Protection to Ebola Virus-Infected Nonhuman Primates",

abstract = "Ebola virus (EBOV) causes lethal disease in up to 90% of EBOV-infected humans. Among vaccines, only the vesicular stomatitis virus platform has been successful in providing postexposure protection in nonhuman primates. Here, we show that an adjuvanted human adenovirus serotype 5 (Ad5)-vectored vaccine (Ad5-Zaire EBOV glycoprotein) protected 67% (6 of 9) and 25% (1 of 4) of cynomolgus macaques when administered 30 minutes and 24 hours following EBOV challenge, respectively. The treatment also protected 33% of rhesus macaques (1 of 3) when given at 24 hours. The results highlight the utility of adjuvanted Ad5 vaccines for rapid immunization against EBOV.",

keywords = "Ebola, adenovirus, nonhuman primates, post-exposure, vaccine",

author = "Gary Wong and Richardson, {Jason S.} and S. Pillet and Trina Racine and Ami Patel and Geoff Soule and Jane Ennis and Jeffrey Turner and Xiangguo Qiu and Kobinger, {Gary P.}",

note = "Publisher Copyright: {\textcopyright} 2015 The Author 2015.",

year = "2015",

month = oct,

day = "1",

doi = "10.1093/infdis/jiv102",

language = "English (US)",

volume = "212",

pages = "S379--S383",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Adenovirus-Vectored Vaccine Provides Postexposure Protection to Ebola Virus-Infected Nonhuman Primates

AU - Wong, Gary

AU - Richardson, Jason S.

AU - Pillet, S.

AU - Racine, Trina

AU - Patel, Ami

AU - Soule, Geoff

AU - Ennis, Jane

AU - Turner, Jeffrey

AU - Qiu, Xiangguo

AU - Kobinger, Gary P.

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Ebola virus (EBOV) causes lethal disease in up to 90% of EBOV-infected humans. Among vaccines, only the vesicular stomatitis virus platform has been successful in providing postexposure protection in nonhuman primates. Here, we show that an adjuvanted human adenovirus serotype 5 (Ad5)-vectored vaccine (Ad5-Zaire EBOV glycoprotein) protected 67% (6 of 9) and 25% (1 of 4) of cynomolgus macaques when administered 30 minutes and 24 hours following EBOV challenge, respectively. The treatment also protected 33% of rhesus macaques (1 of 3) when given at 24 hours. The results highlight the utility of adjuvanted Ad5 vaccines for rapid immunization against EBOV.

AB - Ebola virus (EBOV) causes lethal disease in up to 90% of EBOV-infected humans. Among vaccines, only the vesicular stomatitis virus platform has been successful in providing postexposure protection in nonhuman primates. Here, we show that an adjuvanted human adenovirus serotype 5 (Ad5)-vectored vaccine (Ad5-Zaire EBOV glycoprotein) protected 67% (6 of 9) and 25% (1 of 4) of cynomolgus macaques when administered 30 minutes and 24 hours following EBOV challenge, respectively. The treatment also protected 33% of rhesus macaques (1 of 3) when given at 24 hours. The results highlight the utility of adjuvanted Ad5 vaccines for rapid immunization against EBOV.

KW - Ebola

KW - adenovirus

KW - nonhuman primates

KW - post-exposure

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=84941805575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941805575&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiv102

DO - 10.1093/infdis/jiv102

M3 - Article

C2 - 25957963

AN - SCOPUS:84941805575

SN - 0022-1899

VL - 212

SP - S379-S383

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

ER -

Adenovirus-Vectored Vaccine Provides Postexposure Protection to Ebola Virus-Infected Nonhuman Primates

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this